Previous studies indicated that GCGR aberrant expression might lead to adverse survival in endometrial stromal sarcoma (Davidson et al., 2013), renal cell carcinoma (Schrödter et al., 2016), and non-small cell lung cancer (NSCLC) (Li et al., 2020). This evidence concerns the gene GCGR and hereditary clear cell renal cell carcinoma.